Novel immunisation technology platform
We have developed KISIMA® (‘well’ in Swahili), our first-in-class proprietary immunisation technology platform. The peptide/protein-based vaccination technology is self-adjuvanting and enables the assembly of patented fusion molecules, all essential to generate potent immunity, into one single vaccine.
Our focus is in oncology but KISIMA® is highly versatile and we plan to expand our development pipeline into other cancer indications and therapeutic areas, such as infectious diseases, in the future.
Powerful and highly versatile
KISIMA’s novel immunisation technology enables the assembly of all the components necessary for a potent anti-tumour immune response into one single therapeutic vaccine.
Thanks to this novel proprietary construct, the KISIMA® platform can uniquely and simultaneously provide all the parameters essential for an efficient therapeutic vaccine:
- Induce helper and cytotoxic T cells
- Promote immunological memory
- Target a broad patients population (different antigen and HLA restriction)
KISIMA® immunisation is shown to work in synergy with different immune checkpoint inhibitors in several tumour models.
Potential applications include:
Amal Therapeutics SA
c/o Fondation pour Recherches Médicales
64 av. de la Roseraie
1205 Geneva
Switzerland
